Results 81 to 90 of about 2,036 (191)

Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis

Pediatric Reports
Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy ...
Brody J. Lipsett, Benjamin N. Fogel, Katherine E. Shedlock, Ian M. Paul, Eric W. Schaefer, Ruth E. Gardner, Leah D. Kaye, Steven D. Hicks   +7 more
doaj   +1 more source

Reluctance of parents to immunize their children with nirsevimab

Anales de Pediatría (English Edition)
2025
Piñeiro Pérez, Roi, Galán Arévalo, Sonsoles, Risso, Milagros, Hidalgo Montes, Inmaculada, López Escobar, Alejandro   +4 more
openaire   +3 more sources

Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use

, 2023
   Declarations Funding The preparation of this review was not supported by any external funding. Authorship and conflict of interest M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declare(s) no relevant conflicts of ...
Matt Shirley (7340599)
core   +1 more source

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

The Journal of Clinical Pharmacology
AbstractNirsevimab, a monoclonal antibody with an extended half‐life, is approved for the prevention of respiratory syncytial virus (RSV) disease in all infants in Canada, the EU, Great Britain, and the USA. A population pharmacokinetics (PK) model was built to describe the PK of nirsevimab in preterm and term infants, and to evaluate the influence of ...
Lindsay Clegg, Ed Freshwater, Amanda Leach, Tonya Villafana, Ulrika Wählby Hamrén   +4 more
openaire   +2 more sources

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available.
Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin   +9 more
doaj   +1 more source

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

, 2023
BACKGROUND: Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season.
Greenough, Anne, Papenburg, Jesse, Keller, Christian, Pernica, Jeffrey M., Chi, Hsin, Clement, Pascale, Ahani, Bahar, Gupta, Atul, Kelly, Elizabeth J., Tuffy, Kevin M., Stein, Renato T., Aksyuk, Anastasia A., Danilenko, Daria M., Laubscher, Matt, Morehouse, Christopher, Hashimoto, Koichi, Wadia, Ushma, Richmond, Peter, Cohen, Robert, Lumertz, Magali, Heikkinen, Terho, Abram, Michael E., Yun, Ki Wook, Esser, Mark T., Choi, Eun Hwa, Palomino, María Angélica, Baraldi, Eugenio, Hosoya, Mitsuaki, de Los Santos, Abiel Homero Mascareñas, Rivero-Calle, Irene, Verwey, Charl, Komissarova, Kseniya, Wilkins, Deidre, Martinón-Torres, Federico, Kragten-Tabatabaie, Leyla, Gopalakrishnan, Vancheswaran, Chen, Albert Tian, Priante, Elena, Langedijk, Annefleur C., Nunes, Marta C., Tabor, David E., Brady, Tyler, Lebbink, Robert Jan, Bont, Louis J.   +43 more
core  

Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +1 more source

The Efficacy and Safety of Nirsevimab in the Prevention of RSV Related Infections in Healthy Infants [PDF]

Objective: To assess the efficacy and safety of preventing Respiratory Syncytial virus (RSV) related respiratory illnesses and hospitalization with the use of Nirsevimab, as compared to placebo among infants among healthy early and late preterm infants ...
Mayo, Gabrielle, Ballard, Suyin
core  

Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France

International audienceBackground Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long‐acting monoclonal antibody to prevent RSV‐associated lower respiratory tract infections (LRTI) was ...
Ploin, Dominique, Butin, Marine, Horvat, Côme, Javouhey, Etienne, Hassenboehler, Juliette, Casalegno, Jean‐sebastien, Gillet, Yves, Plaisant, Franck, Ragouilliaux, Corinne, Nunes, Marta C., Chauvel, Cécile, Chakra, Claire Nour Abou   +11 more
core   +1 more source